Postbiotics in Metabolic Disorders

Sumel Ashique has been working as an assistant professor at Department of Pharmaceutical Technology, Bharat Technology, West Bengal, India. He has 4 years of teaching experience. He has achieved 80 publications of International and national accredited reputed journals. He has knowledge in drug delivery, nanotechnology and targeted treatment strategy. He has also 5 granted patents from IP and Australia, with expertise in the field of targeted drug delivery, nanotechnology, gut-microbiome, postbiotics. Currently he is pursuing his PhD degree from Lovely Professional University, Punjab, India (NAAC A++) in the Pharmaceutical Science department.Dr. Shakira Ghazanfar is a prominent microbiologist with a focus on probiotics. Since 2007, she has been a Senior Scientific Officer at the Pakistan Agricultural Research Council (PARC) and founded the Probiotic Development Lab in Islamabad. Dr. Ghazanfar earned her Ph.D. in Microbiology from Quaid-i-Azam University, specializing in gut microbial genomics. Her research has led to AI-driven probiotic products for humans and animals and the invention of a bioinformatics tool named Probio Predict. Currently, she is working on AI development in Pakistan and has published over 100 articles. She has also won several awards, including the Young Biotechnology Award in 2021, continuing to impact the industry with her groundbreaking research in microbial genomics and probiotic advancement.Professor Dr. Naheed Mojgani, with a PhD in Microbiology (1997), heads the Human and Animal Probiotic Research Lab at the Razi Vaccine and Serum Research Institute in Iran. With over 70 peer-reviewed publications and extensive experience in infectious diseases, bacterial vaccines, and probiotics, she has made significant contributions to her field. Dr. Mojgani has received multiple awards, including the Outstanding Researcher Award and recognition from the Iranian Ministry of Education. She serves on several key committees and acts as a senior consultant, facilitating technology transfer for probiotic supplements. Dr. Mojgani has also supervised numerous students and organized workshops, enhancing education in her area of expertise.Dr. Fernanda Maria Policarpo Tonelli, PhD, is an Assistant Professor at Federal University of São João del Rei, Divinópolis-MG, Brazil, where she teaches graduate and post-graduate students. She specializes in biotechnology/molecular biology and has been studying nanomaterials applications (such as delivery and environmental pollution remediation) as well as green synthesis protocols to produce bioactive nanoparticles, and the allelopathic potential of secondary metabolites from plants. The research projects developed by Dr. Tonelli have already resulted in 10 patent and 2 certificates of addition applications, 4 of them already analyzed and granted. She has published 15 books, authored 20 scientific articles and 57 book chapters with international publishers. Dr. Fernanda Tonelli has also dedicated herself to the promotion of science and technology through co-funding a non-governmental organization. She is a member of the editorial board and serves as a reviewer for many prestigious journals. Dr. Tonelli is active in groups of scientists that fight the gender gap in science. Her efforts as a researcher have been recognized with various awards, including For Women in Science Brazil and Under 30 Brazil.

• Chapter 1 Postbiotics: A promising Concept Beyond Pre-and Probiotics in Human Health. Chapter 2 Postbiotics: Beneficial impact on Cardiovascular Disorders. Chapter 3 Postbiotics in Cancer Treatment. Chapter 4 Postbiotics: Beneficial Impact on Diabetes. Chapter 5 Postbiotics: In Gestational Diabetes Mellitus. Chapter 6 Postbiotics: Beneficial impact on obesity. Chapter 7 Postbiotics: Beneficial Impact on Mitochondrial Disorders. Chapter 8 Postbiotics: Role in immune system modulation. Chapter 9 Postbiotics and Their Role in Modulating Inflammation-Driven Metabolic Disorders. Chapter 10 Postbiotics and Gut Microbiota: Gut Health and Oxidative Stress Modulation. Chapter 11 Postbiotic: Current and Future Perspectives in Human Health. Chapter 12 Postbiotics in Managing Insulin Resistance and Glucose Metabolism. Chapter 13 Postbiotics: in metabolic endotoxemia and inflammation in type 2 diabetes. Chapter 14 Postbiotics: In Non-Alcoholic Fatty Liver Disease. Chapter 15 Postbiotics: regulating lipid profiles and hypertension. Chapter 16 Postbiotics: Safety, efficacy and regulatory considerations.